Abstract
Background: Tuberculosis (TB) is threatening disease in China and new therapeutic agents and regimens to treat TB are urgently needed.
Objective: In this study, a DNA vaccine expressing Mycobacterium tuberculosis (MTB) Rv1419 antigen was constructed and its immunogenicity and therapeutic effects were evaluated. Method: Normal mice and TB model mice were immunized intramuscularly three times at two-week intervals with saline, plasmid vector pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA or pVAX1-rv1419 DNA, respectively. Results: At three weeks after the last immunization, flow cytometry showed a higher proportion of CD4+ T cells expressing IFN-γ (Th1) in response to Rv1419 protein in blood from the pVAX1- rv1419 DNA group compared with the saline and vector groups (P<0.05), suggesting a predominant Th1 immune response. Live bacterial loads in lungs and spleens were lower by 0.41 log10 in the pVAX1- rv1419 DNA group than in the saline controls. In addition, pathological changes in the lungs of the DNA vaccinated groups were less. These results suggest that pVAX1- rv1419 DNA could be effective for the treatment of TB, significantly increasing the Th1-type cellular immune response, and inhibiting the growth of MTB. Conclusion: Therefore pVAX1- rv1419 DNA is a candidate for inclusion in a therapeutic combination DNA vaccine against TB.Keywords: DNA vaccine, pVAX1-rv1419 DNA, Immunotherapy, Mycobacterium tuberculosis, Rv1419 protein, Immunization.
Current Gene Therapy
Title:Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis
Volume: 16 Issue: 4
Author(s): Yan Liang, Xiaoyan Zhang, Li Xiao, Xuejuan Bai, Xiaomei Wang, Yourong Yang, Junxian Zhang, Jinying Song, Yinping Liu, Ning Li and Xueqiong Wu
Affiliation:
Keywords: DNA vaccine, pVAX1-rv1419 DNA, Immunotherapy, Mycobacterium tuberculosis, Rv1419 protein, Immunization.
Abstract: Background: Tuberculosis (TB) is threatening disease in China and new therapeutic agents and regimens to treat TB are urgently needed.
Objective: In this study, a DNA vaccine expressing Mycobacterium tuberculosis (MTB) Rv1419 antigen was constructed and its immunogenicity and therapeutic effects were evaluated. Method: Normal mice and TB model mice were immunized intramuscularly three times at two-week intervals with saline, plasmid vector pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA or pVAX1-rv1419 DNA, respectively. Results: At three weeks after the last immunization, flow cytometry showed a higher proportion of CD4+ T cells expressing IFN-γ (Th1) in response to Rv1419 protein in blood from the pVAX1- rv1419 DNA group compared with the saline and vector groups (P<0.05), suggesting a predominant Th1 immune response. Live bacterial loads in lungs and spleens were lower by 0.41 log10 in the pVAX1- rv1419 DNA group than in the saline controls. In addition, pathological changes in the lungs of the DNA vaccinated groups were less. These results suggest that pVAX1- rv1419 DNA could be effective for the treatment of TB, significantly increasing the Th1-type cellular immune response, and inhibiting the growth of MTB. Conclusion: Therefore pVAX1- rv1419 DNA is a candidate for inclusion in a therapeutic combination DNA vaccine against TB.Export Options
About this article
Cite this article as:
Liang Yan, Zhang Xiaoyan, Xiao Li, Bai Xuejuan, Wang Xiaomei, Yang Yourong, Zhang Junxian, Song Jinying, Liu Yinping, Li Ning and Wu Xueqiong, Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis, Current Gene Therapy 2016; 16 (4) . https://dx.doi.org/10.2174/1566523216666161102170123
DOI https://dx.doi.org/10.2174/1566523216666161102170123 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microbial Drug Efflux Proteins of the Major Facilitator Superfamily
Current Drug Targets TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery Efficient Transfection of Phosphorothioate Oligodeoxyribonucleotides by lipofectamine2000 into Different Bacteria
Current Drug Delivery Protein-protein Interfaces Integrated into Interaction Networks: Implications on Drug Design
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery Functionally Engineered Nanosized Particles in Pharmaceutics: Improved Oral Delivery of Poorly Water-soluble Drugs
Current Pharmaceutical Design Current Technology in the Discovery and Development of Novel Antibacterials
Current Drug Targets Eco-Friendly and Highly Efficient Synthesis, Including Multigram Synthesis, of Aldehyde Isonicotinoyl Hydrazones Using Sonochemistry
Letters in Organic Chemistry Enhanced Killing of Intracellular Pathogenic Bacteria by Phenothiazines and the Role of K+ Efflux Pumps of the Bacterium and the Killing Macrophage
Anti-Infective Agents in Medicinal Chemistry Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences New insights on Ethambutol Targets in Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies
Current Drug Targets - Infectious Disorders Role of Old Antibiotics in Multidrug Resistant Bacterial Infections
Current Drug Targets Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery
Combinatorial Chemistry & High Throughput Screening Liposome Technology for Drug Delivery Against Mycobacterial Infections
Current Pharmaceutical Design Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Design and Synthesis of Novel Oxadiazole and Diphenyl Ether Hydrazone Derivatives of Coumarin as Potential Antibacterial Agents
Current Bioactive Compounds Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors
Current HIV Research